Evidence map›Paper›PMID 33603988›Full record

ReviewInternational journal of hematology-oncology and stem cell research2020

How to Assess Founder Effect in Patients with Congenital Factor XIII Deficiency.

Hojat Shahraki, Akbar Dorgalaleh, Majid Fathi, Shadi Tabibian, Shahram Teimourian, Hasan Mollanoori, Alireza Khiabani, Farhad Zaker

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of hematology-oncology and stem cell research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 73% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hojat ShahrakiDepartment of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Akbar DorgalalehDepartment of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Majid FathiDepartment of Medical Biotechnology, School of Allied Medicine, Iran University of Medical Sciences. Tehran- Iran.
Shadi TabibianDepartment of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Shahram TeimourianDepartment of Medical Genetics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Hasan MollanooriDepartment of Medical Genetics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Alireza KhiabaniSchool of Medicine, Bam University of Medical Sciences, Bam, Iran.
Farhad ZakerDepartment of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Iran University of Medical Sciences · IRBam University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congenital factor XIII (FXIII) deficiency is an extremely rare bleeding disorder (RBD) with estimated prevalence of one per 2 million in the general population. The disorder causes different clinical manifestations such as intracranial hemorrhage (ICH), recurrent miscarriage, umbilical cord bleeding, etc. High incidence of the disorder might be due to founder effect. To assess founder effect, haplotype analysis is an important step. For this purpose, suitable and reliable genetic markers such as microsatellites (Hum FXIIIA01 and HumFXIIIA02) and single nucleotide polymorphisms (SNP) are suggested. In the present study we tried to describe evaluation of founder effect in patients with congenital FXIII deficiency via haplotype analysis using suitable genetic markers.

Indexed as

Factor XIII deficiencyFounder effectGenetic markersIntracranial hemorrhage

Identifiers

PMID33603988
PMCPMC7876424
OpenAlexW3114791470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.